Brain signalling
Helps regulate hunger and satiety, reducing appetite and food intake.

This page answers ingredient-level questions. For the branded pen, appointment process and continuing care, the Mounjaro guide remains the main treatment reference.

Tirzepatide acts at both GIP and GLP-1 receptors. It is a different medicine from the GLP-1 receptor agonist semaglutide.
Read the relevant guideMounjaro has authorised uses in type 2 diabetes and adult weight management; assessment follows the relevant indication.
Read the relevant guideYour prescription, response, tolerability and monitoring inform the next step. Do not increase treatment on your own.
Read the relevant guideClinical references: EMA: Mounjaro · EMA: Mounjaro product information
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates receptors involved in glucose regulation and appetite control.
Helps regulate hunger and satiety, reducing appetite and food intake.
Supports glucose-dependent insulin release. Treatment effects and safety still require individual review.
| Your question | The clinical distinction |
|---|---|
| Is it another name for Mounjaro? | Mounjaro is a brand; tirzepatide is its active ingredient. |
| Who may qualify for weight management? | Adult BMI ≥30, or BMI ≥27 and <30 with a weight-related condition, is the starting indication check—not automatic approval. |
| Is it equivalent to a semaglutide dose? | No direct milligram-for-milligram substitution is made. |
| How is progress assessed? | A review considers treatment response, side effects, nutrition and relevant medical monitoring. |
Book the relevant medical assessment; the optional pre-check is not a prescription decision.
Discuss your history, medicines and the evidence needed to make a safe plan.
Receive advice, any onward-care recommendation and an e-prescription only if appropriate.
Use a participating pharmacy and follow the agreed review plan. Medicine cost is separate.
For adult weight management, the starting criteria are BMI 30 or above, or BMI 27 to below 30 with a weight-related condition. Medical history, other medicines and safety checks still matter.
Eligibility and BMI ↗Discuss appetite, nutrition, weight change and side effects at review. A dose increase is not automatic. If changing from semaglutide, the clinician plans the transition; there is no direct milligram conversion.
Mounjaro dosage guide ↗
It acts at both GIP and GLP-1 receptors, which is why it is described as a dual agonist.
This guide explains the ingredient and its clinical context. The Mounjaro page covers the branded treatment pathway and pen-specific guidance.
No. The doctor also checks medical history, safety, medicines and whether the proposed treatment is appropriate.
A doctor can assess a switch. Do not overlap or convert doses yourself; see the dedicated switching guide.
Yes, you can request a review during your stay. Bring the treatment record and allow time for any additional checks.
No. The pharmacy controls stock and dispensing; check the exact strength before making a journey.
English-speaking appointments are available to residents and visitors in mainland Spain, the Balearic Islands and the Canary Islands. The clinician may recommend local examination or tests when needed.
If treatment is prescribed, the QR prescription is sent by email for use at a participating Spanish pharmacy. The consultation fee does not include medicine; confirm the product, price and stock with the pharmacy.
Use a local guide for practical area information, or read how to prepare for an online appointment.
Do not combine or change injectable treatments without a medical plan. Severe persistent abdominal pain or repeated vomiting needs urgent assessment; call 112 for a life-threatening emergency.
Every page includes local pharmacy guidance and links back to this national guide.